Aurobindo Pharma Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026.".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma reported consolidated revenue of INR 8,853 Cr for Q4FY26, up 5.6% YoY, with full-year FY26 revenue at INR 33,653 Cr (6.1% growth). Net profit for Q4 was INR 921 Cr (2.0% YoY increase) and FY26 net profit was INR 3,503 Cr. Europe was a standout performer with Q4 revenue jumping 30.2% YoY to INR 2,795 Cr, crossing the €1bn milestone for FY26. Growth Markets also showed strong momentum with 24.7% YoY growth to INR 980 Cr. However, US revenue declined 13% YoY to INR 3,543 Cr due to lower transient sales. EBITDA margin contracted 104 basis points YoY to 20.3% in Q4. The company received 9 final ANDA approvals from USFDA during the quarter and completed the acquisition of Khandelwal Laboratories (non-oncology) for USD 317mn, ending with a strong net cash position.
The mixed results show good geographic diversification with Europe and Growth Markets offsetting US weakness, though margin pressure and the declining US business remain concerns. The strong cash generation and strategic acquisitions support the company's long-term growth plans despite near-term profitability headwinds.